| Surface Plasmon Resonance (SPR)
XPR
TM
Technology
Bio-Rad Laboratories
Life Science Group
2000 Alfred Nobel Drive
Note to publication: Please do not break
Her
“Pro
cules,
teOn
CA 94547
XPR36” or “Bio-Rad”
onto separate lines. They should be rema
1-800-4BIORAD (1-800-424-6723)
in one unit. Thank you.
For Product Technical Support: lsg_techserv_us@bio-rad.com
Note to publication: Please do not bre
For Liter
ak “Prote
atur
On X
e Request:
PR36” or “
lsg_liter
Bio-Rad”
ature_request@bio-rad.com
onto separate lines. They should be re
www
main
.disco
one un
ver
it.
.bio-r
Thank
ad.com
you.
ProteOn
TM
XPR36 Protein Interaction Array System:
ProteOn
TM
High-Throughput
XPR36 Protein Inter
ProteOn
Antibody Scr
action
eening and Epitope Mapping
Array System:
High-Throughput
TM
XPR36 Protein Inter
Antibody Screening and Epitope Mapping
action Array System:
Monoc
Monoclonal antibodies are of particular interest in basic
lonal
High-Throughput
antibodies are of particular interest
Antibod
in basic
y Scr
biomedical
eening and Epitope Mapping
Anti-mouse IgG
research
biomedical research and for the diagnosis and treatment
and for the diagnosis and treatment of various diseases.
Screening,
of various diseases.Monoclonal antibodies are of particular interest in basic
profi ling, and
Screening,
production
profiling,
of antibodies
and production of
involve tedious and
Anti-mouse IgG
1
time-consuming
biomedical research and for the diagnosis and treatment
procedures. Bio-Rad now offers the ProteOn XPR36
protein
antibodies involve tedious and time-consuming procedures.
interaction
of various diseases.
array system,
Screening,
a label-free,
profiling,
multiplex
and production of
system for

1
rapid
Bio-Rad now offers the ProteOn XPR36 protein interaction array
screening
antibodies involve tedious and time-consuming procedures.
and comprehensive kinetic profi ling of antibody

Mouse anti-human
interactions.
system, a label-free, multiplex system for rapid screening and IL-12 supernatants
comprehensive kinetic profiling of antibody interactions.
Bio-Rad now offers the ProteOn XPR36 protein interaction array
Mouse anti-human
system, a label-free, multiplex system for rapid screening and IL-12 supernatants
The ProteOn
comprehensive kinetic profiling of antibody interactions.
XPR36 instrument is based on surface plasmon
2
resonance The Prote(SPR) On XPtechnologR36 instruy mand ent imeets s basedthe on challenges surface plasof mohigh-n
2
throughput
resonan
T
c
h
e
e
processing


(
P
S
r
P
o
R
te
)
O
t
n
e

c
X
h
P
n
R
by
o
3
lo
6
g

bringing
in
y
s
a
tr
n
u
d
m
m
en
e
t
a
e
is
ts

novel
b
t
a
h
s
e
e

d
c

h
o
one-shot
a
n
l

l
s
e
u
n
r
g
fa
e
c
s
e


o
p
kinetics
f
l

a
h
s
i
m
gh
o
-
n
Regeneration —
approach
through
r
to
p
e
u
s
the
t
o

n
p
a
ro
n
stud
c
c
e
e

s
(S
y
si
P
n
of
R
g
)


protein
b
te
y
c

h
b
n
ri
o
n
lo
g
interactions.
g
in
y
g
a

n
a
d
n
m
ov
e
e
e
l
t


s
o
The

n
th
e
e
-

system’
s
c
h
h
o
a
t
ll

e
k
n
in
g
s
e
e
t
parallel
s
i

c
o
s
f high-
Five concentrations of IL-12, and ready for next
4
running buffer
R
p
e
a
g
n
e
e
n
l
e
o
ra
f
t
6
and
ion —
ap
real-time
proac
th
h
r

o
to
u

sample
g
th
hp
e
u
s
t
t
p
u
r
d
processing
o
y
c

e
o
s
f
s
p
in
r
g
o

t
b
e
y
in

ca
b
i
r
n
i
pabilities
n
t
g
e
i
r
n
a
g
c

t
a
io
n
n
o
s
enable
v
.
e
T
l
h
on
e
e
s
-
simultaneous
y
s
s
h
t
o
e
t
m
ki
’
n
s
e
p
tic
a
s
rallel Five concentrations of IL-12, and
re
s
a
u
d
p
y
e
f
r
o
n
r
a
n
ta
e
n
xt
ts
acquisition
running buffer panel of 6
4
and rea
a
l-
p
t
of
p
im
ro
e
comprehensive
a

c
s
h
a

m
to
p
th
le
e


p
s
r
t
o
u
c
d
e
y
s
o
da
s
f
in
p
ta
r
g
o

t
c
for
e
a
in
p

a
i
36
n
b
te
ili
r
t
molecular
a
ie
c
s
tio
e
n
n
s
a
. T
b
h
le
e

interactions

s
s
i
y
m
st
u
e
l
m
ta
’
n
s
e
p
o
a
u
ra
s
llel
supernatants
3
— without the need for regenera
acquisitaionnd oref acl-otmi per esahmenpsleiv per od
tion.
caetsas finogr 3ca6p maboillietiecsu leanr aibnlte rsaimctuioltnas neous
Power of one-shot kinetics:
3
A complete kinetic profile of
acquisition of c mprehensive data for 36 molecular interactions
Pow6 esru opf eornea-tsahnott akninteibtiocds: ies in
Protocol
— withou
for
t the
Selection
need for reg
and
enerat
Ranking
ion.
of 250 Mouse
A c
o
o
n
m
e
p
c
le
y
t
c
e
le
kinetic profile of
— without the need for regeneration.
6 supernatant antibodies in
Monoc
one cycle
Protoc
lonal
ol for S
Antibody
election an
Supernatants
d Ranking of 250
against
Mouse M
Human
Interleukin 12 (IL-12)
onoclonal
Protocol for Selection and Ranking of 250 Mouse Monoclonal
1.
A
Anti-mouse
ntibody Sup
Antibo
IgG
ern
dy S
is
ata
up
immobilized
nts Against
ernatants Aga
covalently
Human In
inst Huma
on
terl
n In
six
euk
terle
microfl
in 12
ukin 1

(
uidic
IL-12)
2 (IL-12)
channels
1. Anti-
using
mouse
1. Anti
a

-m
ProteOn
IgG is im
ouse IgG
GLM
mob
is im
sensor
ilized co
mobiliz
chip
vale
ed co
(see
ntly o
vale
F
n
igure
n six m
tly on
1
six
for
icro
m
protocol
fluidic
icrofluidic
Fi
F
g. 1. Workflow for high-throughput antibody screening.
F
i
i
g
g
.
. 1
1
.
.
W
W
o
o
r
r
k
k
fl
f
ow
low
fo
f
r
o
h
r
i
h
g
i
h
g
-
h
th
-t
r
hr
ou
o
g
u
h
g
p
h
u
p
t
u
a
t
nt
a
ib
n
o
ti
d
b
y
o

d
s
y
cr
s
e
c
e
r
n
e
in
e
g
n
.
ing.
workfl
cha

n
o
n
w).
el
c
s
h

a
u
n
s
n
in
e
g
ls


a
u

s
P
in
ro
g
t

e
a
O
P
n
ro
G
te
L
O
M
n

G
se
L
n
M
s

o
se
r
n
c
s
h
o
i
r
p


c
(
h
s
i
e
p
e
(

s
F
e
ig
e
u
F
r
i
e
gu
1
re
f

o
1
r
for
10
7
2.
p
Six
roto
different
col workfl
unpurifi
ow).
ed mouse anti-human IL-12 supernatant
10
7
protocol workflow).
solutions
2. Six d
are
2
iff
.
e
S
r
i
e
injected
x
n
d
t
i

f
u
fe
n
r
p
e
u
n
through
t
r

i
u
fi
n
e
p
d
u
m
rifi
o
e
six
u
d
s
m
e
orthogonal

o
a
u
n
s
t
e
i-

h
an
u
t
m
i-h
a
u
channels
n
m
IL
a
-
n
1
I
2
L-
s
1
u
2
in
p
s
e
u
parallel.
r
p
n
e
a
r
t
n
a
a
n
t
t
a

nt
0.01 nM
0.01 nM
0.
0
1
.

1
n

M
nM
Specifi
solu

t
c
ion
mouse
s
s
o
a
lu
r
t
e
io

n
in
antibodies
s
j

e
a
c
re
te
i
d
n

je
th
c
r
t
o
e
are
d
u

g
th
h
ca
r

o
s
u
i
ptured
x
g

h
o

r
s
t
i
h
x
o
o
g
by
r
o
th
n
o
the
a
g
l
o
c
n
h
immobilized
a
a
l
n
ch
n
a
e
n
ls
n

e
in
ls


p
in
a
anti-

r
p
a
a
ll
r
e
a
l
l
.
l

el. ]
–1
]
mouse IgG caSpecific
S
m
pe
o
c
pture au
ifi
s
c
e
m
a
o
ngent.
u
ti
s
b
e
o
a
d
n
ie
ti
s
b

o
a
d
re
ie

s
c

ap
re
tu
c
r
a
e
p
d
t

u
b
r
y
e

d
t

h
b
e
y


i
t
m
he
m
im
ob
m
il
o
iz
b
e
il
d
iz

e
a
d
n

t
a
i-
nti-
s
–1
s
–1
–1
3.
m
F
o
ive
use
concentra
mIgGou csea pIgtuG
tions
r ec aapgtuer
of
net .a g
purifi
ent.


ed IL-12 antigen are applied
[M [M 1.0
1
n
.0
M
nM
k
a 10
6
k
a 10
6
simultaneously
3. Five c3o. nFciven
in
ctoran
the
tcioent
orienta
sr aotfio pnus
tion
roifif epdu
of
rIiLfi-e
the
1d2 IL a-
original
1n2ti gaennti ga
anti-mouse
erne arpep alipepd lied
IgG
ca
s
pture
imult
antibodies.
an
si
e
m
o
u
u
l
s
ta
ly
n

e
in
o


Running
u
t
s
h
l
e
y

i
o
n
r

i
t
e
h
n
e
buffer
t

a
or
t
i
i
e
o
n
n
t

a
is
o
t
f
io

injected
t
n
h

e
o

f
o
t
r
h
ig
e
i
o
n
in
r
a
ig
l
the

i
a
n
n
a
t
l
i
sixth
a
-m
nti
o
-
u
m
channel
s
o
e
u

s
Ig
e
G
IgG
as
c
a
ap
double
ture
c
a
a
n
p
reference
t
t
i
u
b
r
o
e
d
a
i
n
e
t
s
ib
.
o
to
R
d
u
i
correct
e
n
s
n
.
in
R
g
u

n
b
n
for
u
in
ff
g
e
an

r
b

u
i
y
s
ff

decay
e
in
r
je
is
c
i
t
n
e
j
of
e
d
c
i
the
t
n
e

d
t

h
i
ca
n
e


t
ptured
s
h
i
e
x

t
s
h
i

x
c
th
h
anti-

a
c
n
h
n
an
e
n
l
el
10
1
n
0
M
nM
IL-12
as a
from
dou
as
b
the

l
a
e


d
r
anti-mouse
e
ou
fe
b
r
l
e
e
n
r
c
ef
e
e

r
t
e
o
n

IgG.
c
c
o
e
r
t
r

o
e
Thirty-six

c
c
t
o

r
f
r
o
e
r
c
a
t
n
fo
y
r
sensorgrams


d
a
e
n
c
y
a
d
y
e

c
o
a
f
y
t

h
o
e
f

t
(six
c
h
a
e
p
c
t
sets
a
u
p
re
tu
d
r
of

e
a
d
n
a
ti
n
-
ti-
10
5
six) are genera
IL-12 f
ted
rom
simultaneously
the anti-mouse
,
Ig
providing
G. Thirty-si
the
x sen
associa
sorgram
tion
s (si
and
x sets of
10
5
10
–5
10
–4
10
–3
10
–2
dissocia
IL-12
tion kinetics of all six antibodies.
from the anti-mouse IgG. Thirty-six sensorgrams (six sets of
10
–5
10
–4
10
–3
10
–2
six) are generated simultaneously, providing the association and
k
d
[s
–1
]
4. IL-12
six) ar
antigen-antibod
e
d
g
is
e
s
n
o
e
c
r
i
a
a
t
t
e
io
d
n


s
k
i
i
m
n
y
e
u
pairs
ti
l
c
ta
s
n
o
e
f
are

o
a
u
ll
s

removed
s
ly
ix
,
a
p
n
ro
ti
v
b
i
o
d
using
d
in
ie
g
s

.
t

h

diluted

e

assoc
phosphoric
iation and
k
F
d
[s
–1
]
Figig. . 2. 2. IIso--aafffininitityy pplolot t oof f asasoscoicaitaiotino n anadn dd isdsiosscoiactiaotni orn atera ctoe nstants
acid,
dis

s
allo
oci
wing
a
4
t
.
i

o
IL
n
-

ca1
k
2
in
pture
e
an
ti
t
c
ig
s
e

and
o
n
f
-

a
a
n
l
analysis
l
t

i
s
b
i
o
x
d
a
y
n
p
ti
a
b
of ir
o
s
d
a a
ie
rnew e
s

.
r

e

m

panel

Fig. 2. Iso-affinity plot of association and dissociation rate constants
oved of usi6 nghybridoma diluted
o
c
o
b
o
b
ta
n
t
i
s
a
n
t
in
e
a
e
d
n
d

t
f
s
fr
ro
o
o
m
b
m
t

a
a
a
i
n
n
n
t
e
ti
i-
d
-IL
IL
f
-
-
r
1
1
o
2
2
m
sc
s
a
r
c
n
e
re
t
e
i
e
-
n
n
I
i
L
n
i
-
g
n
1

g
2
ex
e
s
p
x
c
e
p
r
r
e
im
e
e
ri
n
e
m
i
n
n
t
e
g
.
nt
e
T
s
x
h
.
p
e
T
e
a
h
r
e
i
f
m
fin
a
e
it
ff
n
y
in
t
r
s
a
it
.
ng
y
T
e
ra
h

n
e
was
0.1–10 nM, with highest-affinity variants being the be t candidates for fugrteh ewr as
superna
4. IL-1
tants.
2 antigen-antibody pairs are removed using diluted
0.
a
phosphoric acid, allowing capture and analysis of a new panel of 6
1s
f
–e
f
1l
ien
0c
i

tt
n
y io
Mn
ra
,a
n
wn
gd
it
e
hp
wu
hri
ai
gfi
s
hcae
0t
si
.o
t
1
-n
–
a. f
1
fi
0
nit
n
y
M
v
,
ar
w
ia
i
n
th
ts
h
b
ig
e
h
in
e
g
s
t
t-
h
a
e
f

f
b
in
e
i
s
t
t
y
c
v
a
a
n
r
d
ia
id
n
a
ts
tes for further
phosphoric acid, allowing capture and analysis of a new panel of 6
se
b
l
e
e
i
c
n
t
g
ion
th
a
e
n
b
d
e
p
s
u
t
r
c
if
a
ic
n
a
d
ti
i
o
d
n
a
.
te

s for further selection and purification.
hybridoma supernatants. Summary
Repea
hybr
ting
idom
the
a s
c
u
yc
pe
le
rn
42
ata
times
nts.
on the same chip allows determination
Summar
Su
Th
m
e
ma
u
y
r
lt
y
iplexing and one-shot kinetics capabilities of the
of a comprehensive Repeating thkinetic e cycleprofi 42 t ile mefor s oall n th250 e samsupernae chip atants llows in less
The
ThB
multiplexing
eio m-Rualdti pPlreoxteinO
and
gn aXnP
one-shot
dR 3o6n es-yshteo
kinetics
mt kpinroevtiidc
ca
es ac
pabilities
appoawbeirlfituiel
of
asp op
the
fr otha
Bio-Rad
ce h for
than
Rep
13
eat
hours,
idnegt ethrm

e
enabling
incaytciolen 4o2f
ra
at icm
pid o
emsp
and
orenh et
high-throughput
hnes ivsea mkinee ctihc ipr oafilllo
screening e
w fos r all 250
for
ProteOn
Bitoh-eR ra
XPR36
dp idP rsoctre
system
Oeni nXgP oRf
provide
3 la6r gsey sntue
a
m
po
b ep
werful
rso voifd hey ba
a
r
pproach
ipdowmear fsul
for
p aeprnp
the
artoaan
ra
ctsh
pid
, fa or
high-affi
determ
nity cell lines (see F
i
s
n
u
a
p
t
e
io
r
n
a
o
ta
f
n
a
t

s
c
i
o
n
m
le
p
s
r
sigure 2).
e

h
th
e
a
n
n
s
1
iv
3
e


h
k
o
in
u
e
rs
t
,
i

c
e

n
p
a
ro
bl
fi
in
le
g


f
r
o
a
r
p

i
a
d
l

l
a
2
n
5
d
0
high-
screening
th
p
e
r

e
r
v
a
i
p
ou
i
of
d
s

l
s
y
large
c
t
r
im
ee
e
n
-
numbers
c
in
o
g
n

s
o
u
f
m
la
in
r
of
ge
a
hybridoma
n
d
u

m
la
b
o
e
r
r
i
s
o

u
o
superna
s
f


c
h
o
y
m
br
p
i
o
d
tants,
n
o
e
m
n
a
t

i

n
s
a

u
t
previously
h
pe

r
a
n
r
a
ea
ta
o
n
f
ts, a
superna
th
ta
ro
n
u
ts
g

h
in
p

u
le
t
s
s
s
c

r
t
e
h
e
a
n
n
in
1
g
3
fo
h
r
o
h
u
ig
r
h
s
-
,
a
e
ffi
n
n
a
i
b
ty
li

n
ce
g
l

l
r
l
a
in
p
e
id
s

(
a
s
n
e
d
e

F
h
i
i
g
g
u
h
r
-
e 2).
time-consuming
pr
a
e
n
v
t
i
i
o
b
u
od
s
y
ly
r
t
e
i
s
m
e
e
a
and
-
rc
c
h
o
.
n

laborious
suming a
component
nd laborious
in
co
the
mp
area
onen
of
t in
antibod
the are
y
a of
throughput screening for high-affinity cell lines (see Figure 2).
research.
antibody research.
Protocol Guide ı 2008 View entire protocol online at www.biotechniques.com/protocol ı BioTechniques ı 71
07-0583_protocol_final.indd 1 9/10/07 10:34:45 AM
07-0583_protocol_final.indd 1 9/10/07 10:34:45 AM
BioRad OneShot Protocol.indd 71 10/26/07 12:07:53 PM
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76